INAB

In8bio Inc.distress 7/10 · high distress / dilution risk

$1.23-1%today-53% from 52w high

in8bio.com18 employeesFounded 2016New York, NYBiotechnology

Oncology 1

Lead: acute myeloid leukemia · est. market ~$15B (approx, global)

Revenue

pre-revenue

Liquidity

$22M

Runway

1.5 yrs

Shares 1y

+117%

Price & events

-50.4% over 6M

CatalystRating changeDilutionFinancingdashed = today

-0.8%

-14.6%

-15.8%

-18.0%

-50.4%

-48.1%

-95.3%

—

-99.6%

All

Overview

Market Cap: $12.11M
Volume: 22.60K
52 Week Range: $1.21 – $2.59
Total Shares: 9.85M
Float Shares: 7.21M
Short %: 0.40%
% Held by Insiders: 13.40%
% Held by Institutions: 38.11%
RVOL: 0.49x
Beta: 0.22

Pipeline stages · 1 programs

Autologous genetically modified gamma-delta T cells, Allogeneic genetically modified gamma

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

Pipeline · 1 trials · 0 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
2025-12	Phase 1/2	Autologous genetically modified gamma-delta T cells, Allogeneic genetically modified gamma	Glioblastoma	4	active not recruiting

Catalyst news & presentations · 11

2026Guided 40%readoutPhase 1INB-100 · Additional long-term follow-up resultsSEC 8-K
2025trial initiationsecondaryPhase 2INB-100 · Initiate registrational trial for INB-100 in AMLSEC 8-K
late 2025readoutPhase 2INB-400 · Additional data update on mPFS and other efficacy endpoints.SEC 8-K
first half of 2025enrollment completesecondaryPhase 1INB-100 · Complete enrollment of expansion cohort to approximately 25 patientsSEC 8-K
first half of 2025readoutPhase 1INB-100 · Expansion cohort and control data expectedSEC 8-K
Q1 2025regulatory submissionFiled (NDA/BLA)INB-100 · IND submission for registrational trial of INB-100 in AMLSEC 8-K
March 3, 2025 at 10:30 a.m. ETconferencedata presentationsecondaryINB-619 · Webcast at TD Cowen Health Care Conference discussing the new gamma-delta TCE platform.SEC 8-K
end of 2024enrollment completesecondaryPhase 1INB-100 · Full enrollment of 10-patient expansion cohort expectedSEC 8-K
Q4 2024conferencedata presentationsecondaryPhase 1INB-200 · Updated clinical data from INB-200 Phase 1 trialSEC 8-K
2024-09-04trial discontinuedINB-400 · Suspended enrollment in Phase 2 trial for newly diagnosed glioblastomaSEC 8-K
2024-08-12fda agreementINB-100 · FDA provided guidance on registrational path for INB-100 as post-transplant maintenance therapy with relapse-free survival as primary endpointSEC 8-K

Approved drugs (0)

none — clinical-stage

Capital structure — dilution & financing

Shares out: 9,847,089 · 2 offerings/1y · 1 PIPEs

2026-06-018-Kmaterial_agreement
2026-06-01424B5offering
2026-05-19EFFECTshelf_effective
2026-05-18S-3/Ashelf_registration
2026-01-30424B3offering
2026-01-28EFFECTshelf_effective
2026-01-20S-3shelf_registration

🔒 Positioning — Pro

Short interest / days-to-cover, insider buys & sells.

Upgrade to Pro

🔒 Top holders — Pro

Institutional ownership + quarter-over-quarter accumulation/trimming.

Upgrade to Pro

Wall St ratings

no consensus

2026-03-13HC Wainwright & Co.Buy
2025-03-14HC Wainwright & Co.Buy
2025-02-12HC Wainwright & Co.Buy
2025-02-11Jones TradingHold → Buy
2024-11-26HC Wainwright & Co.Buy
2024-11-13HC Wainwright & Co.Buy

Competitors — acute myeloid leukemia

ABBVAbbVie Inc.$451.1B · D2
SLSSELLAS Life Sciences Group, Inc.$2.2B · D4
SNDXSyndax Pharmaceuticals Inc$1.9B · D5
KURAKura Oncology, Inc.$917M · D5
FHTXFoghorn Therapeutics Inc.$303M · D4
DTILPRECISION BIOSCIENCES INC$185M · D6
BMEABiomea Fusion, Inc.$90M · D6
MBRXMoleculin Biotech, Inc.$11M · D8
APVOAptevo Therapeutics Inc.$6M · D7
BPTHBIO-PATH HOLDINGS, INC.$2M · D9

Recent news

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.